SCHEMBL4344288

SCHEMBL4344288

O=C(c1ccccc1)c1cnc2[nH]ccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 7/20 0.55
AXL P30530 2/20 0.55
MAP4K4 O95819 3/20 0.55
ROS1 P08922 3/20 0.55
FLT4 P35916 3/20 0.55
KDR P35968 3/20 0.55
ROCK1 Q13464 3/20 0.55
MINK1 Q8N4C8 3/20 0.55
AURKB Q96GD4 3/20 0.55
MAP4K5 Q9Y4K4 3/20 0.55
CDK7 P50613 2/20 0.55
CHEK2 O96017 2/20 0.55
CDK1 P06493 2/20 0.55
FES P07332 2/20 0.55
FER P16591 2/20 0.55
IRAK1 P51617 2/20 0.55
PKN2 Q16513 2/20 0.55
MARK2 Q7KZI7 2/20 0.55
SLK Q9H2G2 2/20 0.55
MKNK2 Q9HBH9 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27732330 0.92 RIPK1 (0.56) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL13356975 0.85 RIPK1 (0.55) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL3353411 0.85 RIPK1 (0.51) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL27677303 0.85 NAMPT (0.57) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL298264 0.83 RIPK1 (0.55) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL2182346 0.81 HPGD (0.51) CDK8MAP4K4ROS1FLT4KDR
SCHEMBL12410716 0.79 CDK8 (0.67) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL4117054 0.79 RIPK1 (0.70) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL29378344 0.79 RIPK1 (0.70) CDK8AXLMAP4K4ROS1FLT4
SCHEMBL4128043 0.78 KDR (0.63) CDK8AXLMAP4K4ROS1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090274674-A1 Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them LES LABORATOIRES SERVIER (FR) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090274674-A1 Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them CYP3A4, CYP2C19, CYP3A43 CDK8 783/4885AXL 424/4885MAP4K4 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.